Immuneering Announces $25 Million Private Placement

Core Insights - Immuneering Corporation has entered into a definitive securities purchase agreement for a private placement expected to yield approximately $25 million in gross proceeds before fees and expenses [1] - The company is focused on developing a new category of cancer medicines called Deep Cyclic Inhibitors, with its lead product candidate, atebimetinib, currently in a Phase 2a trial for pancreatic cancer [2][5] - The recent data from the Phase 2a trial shows a 94% overall survival rate at 6 months for patients treated with atebimetinib in combination with mGnP, significantly higher than the 67% observed in the standard of care [2] Financing Details - The private placement involves the sale of 6,329,113 unregistered shares of Class A common stock at a price of $3.95 per share, representing a 15% premium over the last reported closing price [2] - Investors will also receive purchase warrants for an aggregate of 2,848,096 shares at an exercise price of $5.50 per share, with a five-year exercisability period following registration for resale [2] Company Overview - Immuneering is a clinical-stage oncology company dedicated to improving the survival of cancer patients through innovative treatments [5] - The company is developing atebimetinib as an oral, once-daily treatment aimed at enhancing durability and tolerability for MAPK pathway-driven tumors, including pancreatic cancers [5]